1. Assessing for coding mutations in genomic DNA by polymerase chain reaction (PCR) amplification and DNA sequence determination of the 10 coding exons of MAGT1. 2,3 2. Assessing for loss of MAGT1 expression by real-time qRT-PCR, followed by targeted genomic sequencing of coding and noncoding gene regulatory regions of the MAGT1 locus. 3. Assessing large-scale deletions of the MAGT1 gene by comparative genomic hybridization.
Analytical validation
Genomic variants should be validated by investigating deficiencies in MAGT1 expression or function as indicated by one of more of the following means:
1. Decreased MAGT1 mRNA on real-time qRT-PCR. 
Diagnostic setting
Diagnostic characteristics: As an X-linked disorder, XMEN disease will be mostly found in males, but it may also be found in females as male patients can often survive to reproductive age. Features strongly indicative of XMEN disease include persistent Epstein-Barr virus (EBV) viremia (410 000 copies in viral load estimations), often with a history of EBV+ lymphoma, and/or a CD4:CD8 T-cell ratio of~1 or less with a normal lymphocyte count or mild to moderate lymphopenia. Other nonspecific features that may be associated with XMEN disease include history of recurrent sinopulmonary and viral infections, hypogammaglobulinemia (IgM, IgG and/or IgA), variable antibody response to vaccinations (eg tetanus, diphtheria and pertussis) and neutropenia. XMEN disease should be suspected in any male patient with a history of lymphoma in multiple male family members and elevated titers of EBV in circulation (Table 2) .
Differential diagnosis: The poor control of EBV in XMEN disease is also found in several other similar genetic disorders, including X-linked lymphoproliferative (XLP) syndrome secondary to signaling lymphocytic activation molecule (SLAM)-associated protein (SAP) deficiency, interleukin-2-inducible tyrosine kinase (ITK) deficiency, X-linked inhibitor of apoptosis (XIAP) deficiency secondary to mutations in BIRC4, CD27 deficiency, coronin 1A deficiency, familial hemophagocytic lymphohistiocytosis secondary to perforin 1 (PRF1) or syntaxin binding protein 2 (STXBP2) deficiency, or the as yet genetically unidentified cause(s) of chronic active EBV (CAEBV) disease. 3 XMEN patients usually have a decreased CD4:CD8 ratio, and their absolute CD4+ T-cell count can sometimes fall below 400. Hence the differential diagnosis may also include idiopathic CD4 lymphopenia.
Predictive testing: This does not apply currently as all patients identified thus far with a MAGT1 variant have XMEN disease features.
Risk assessment in relatives: As this is an X-linked recessive genetic disorder, all female offspring of affected males will be carriers, while the carrier status of all other female relatives of the index case will need to be determined by genetic testing. Knowledge of carrier status will guide prenatal diagnostic testing or pre-implantation genetic diagnostic testing for family planning.
TEST CHARACTERISTICS

Analytical sensitivity (proportion of positive tests if the genotype is present)
Insufficient data to comment.
Analytical specificity (proportion of negative tests if the genotype is not present)
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.
Unknown, as the disease is clinically similar to many primary immunodeficiency disorders that suffer from chronic EBV infection as listed in the differential diagnosis in 1.9.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.
Unknown, only those with a consistent clinical history are tested so far.
Positive clinical predictive value (life-time risk to develop the disease if the test is positive)
Unknown, but all XMEN patients found thus far have a history of chronic EBV viremia. Whether there are any patients with loss-offunction mutations in MAGT1 who do not exhibit any of the features of XMEN disease listed under 1.9 remains unknown.
Negative clinical predictive value (probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: Not applicable, as XMEN disease is not uniquely defined clinically. There are several other genetic diseases listed under the differential diagnosis in 1.9 that have clinical features similar to XMEN disease. Thus, there is a possibility for any patient with no MAGT1 mutations 
